A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years
Current standard of care (SoC) for the prevention of pneumococcal disease among Mexican adults aged ≥60 years is a sequential regimen of pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPSV23). This study estimated the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136225000762 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849237504822083584 |
|---|---|
| author | Jose Luis Huerta An Ta Elizabeth Vinand Gustavo Ivan Torres Warisa Wannaadisai Liping Huang |
| author_facet | Jose Luis Huerta An Ta Elizabeth Vinand Gustavo Ivan Torres Warisa Wannaadisai Liping Huang |
| author_sort | Jose Luis Huerta |
| collection | DOAJ |
| description | Current standard of care (SoC) for the prevention of pneumococcal disease among Mexican adults aged ≥60 years is a sequential regimen of pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPSV23). This study estimated the effect of replacing the current SoC with a single dose of 20-valent PCV (PCV20) in the Mexican adult national immunization program (NIP).A probabilistic cohort model with a Markov framework was developed with an annual cycle to compare the cost-effectiveness of PCV20 versus SoC (PCV13 → PPSV23) from the Mexican public health sector perspective over a lifetime horizon. Costs and benefits were discounted at 5 % annually. Vaccine effectiveness was estimated from PCV13 clinical trial and PPSV23 effectiveness studies as well as the disease impact due to PCV13 → PPSV23 observed in Mexico. Other model inputs including epidemiology, costs, and utilities were sourced from Mexican-specific data. Uncertainty relating to model inputs was evaluated by deterministic and probabilistic sensitivity analyses as well as scenario assessments.PCV20 was estimated to be the dominant vaccination strategy versus SoC (PCV13 → PPSV23) in the Mexican adult population aged ≥60 years. PCV20 was associated with more clinical benefits and a cost saving of approximately 7 billion Mexican pesos compared with SoC at the population level. The results were shown to be robust in all sensitivity and scenario analyses.The replacement of the current SoC with PCV20 in the Mexican NIP is expected to simultaneously reduce the clinical burden of pneumococcal disease and associated medical costs among adults aged ≥60 years. |
| format | Article |
| id | doaj-art-abe20a94b3754315b9bd01b29b00384f |
| institution | Kabale University |
| issn | 2590-1362 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj-art-abe20a94b3754315b9bd01b29b00384f2025-08-20T04:01:57ZengElsevierVaccine: X2590-13622025-08-012510068210.1016/j.jvacx.2025.100682A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 yearsJose Luis Huerta0An Ta1Elizabeth Vinand2Gustavo Ivan Torres3Warisa Wannaadisai4Liping Huang5Pfizer, MexicoMexico Cytel, UKMexico Cytel, UKPfizer, MexicoPfizer, UKGlobal Value and Evidence, Vaccines, Pfizer Inc, NY, USA; Corresponding author.Current standard of care (SoC) for the prevention of pneumococcal disease among Mexican adults aged ≥60 years is a sequential regimen of pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPSV23). This study estimated the effect of replacing the current SoC with a single dose of 20-valent PCV (PCV20) in the Mexican adult national immunization program (NIP).A probabilistic cohort model with a Markov framework was developed with an annual cycle to compare the cost-effectiveness of PCV20 versus SoC (PCV13 → PPSV23) from the Mexican public health sector perspective over a lifetime horizon. Costs and benefits were discounted at 5 % annually. Vaccine effectiveness was estimated from PCV13 clinical trial and PPSV23 effectiveness studies as well as the disease impact due to PCV13 → PPSV23 observed in Mexico. Other model inputs including epidemiology, costs, and utilities were sourced from Mexican-specific data. Uncertainty relating to model inputs was evaluated by deterministic and probabilistic sensitivity analyses as well as scenario assessments.PCV20 was estimated to be the dominant vaccination strategy versus SoC (PCV13 → PPSV23) in the Mexican adult population aged ≥60 years. PCV20 was associated with more clinical benefits and a cost saving of approximately 7 billion Mexican pesos compared with SoC at the population level. The results were shown to be robust in all sensitivity and scenario analyses.The replacement of the current SoC with PCV20 in the Mexican NIP is expected to simultaneously reduce the clinical burden of pneumococcal disease and associated medical costs among adults aged ≥60 years.http://www.sciencedirect.com/science/article/pii/S2590136225000762Pneumococcal diseasePCV20Pneumococcal conjugate vaccineAdultMexicoNational immunization program |
| spellingShingle | Jose Luis Huerta An Ta Elizabeth Vinand Gustavo Ivan Torres Warisa Wannaadisai Liping Huang A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years Vaccine: X Pneumococcal disease PCV20 Pneumococcal conjugate vaccine Adult Mexico National immunization program |
| title | A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years |
| title_full | A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years |
| title_fullStr | A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years |
| title_full_unstemmed | A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years |
| title_short | A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years |
| title_sort | cost effectiveness analysis of the 20 valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among mexican adults aged ≥60 years |
| topic | Pneumococcal disease PCV20 Pneumococcal conjugate vaccine Adult Mexico National immunization program |
| url | http://www.sciencedirect.com/science/article/pii/S2590136225000762 |
| work_keys_str_mv | AT joseluishuerta acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT anta acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT elizabethvinand acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT gustavoivantorres acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT warisawannaadisai acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT lipinghuang acosteffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT joseluishuerta costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT anta costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT elizabethvinand costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT gustavoivantorres costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT warisawannaadisai costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years AT lipinghuang costeffectivenessanalysisofthe20valentpneumococcalconjugatevaccineforthepreventionofpneumococcaldiseaseamongmexicanadultsaged60years |